Physician profile
Emily Wall
NPI 1497523609
$3,464.49
in general payments reported to CMS, 2019-2025
26 companies · $1,589 in 2025
The $1,589 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,875 · 2025: $1,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,464.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $578.42 | 2024-2025 | |
| Novo Nordisk INC | $389.04 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $259.86 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $250.37 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $246.14 | 2024-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $210.08 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $191.49 | 2024-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $171.98 | 2024-2025 | |
| Lilly USA, LLC | $170.11 | 2024 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $154.72 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.09 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $107.99 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $107.70 | 2024 | Cologuard Collection Kit |
| Abbott Laboratories | $106.68 | 2024-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $93.81 | 2024-2025 | Gemtesa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $51.30 | 2024-2025 | Otezla, Repatha, Repatha |
| Mylan Specialty L.P. | $40.15 | 2024 | Yupelri |
| Shield Therapeutics INC | $38.01 | 2024-2025 | |
| Insulet Corporation | $37.29 | 2024 | Omnipod |
| Scilex Pharmaceuticals INC. | $23.69 | 2024 | |
| Astellas Pharma US INC | $20.59 | 2024 | Veozah |
| Paratek Pharmaceuticals, INC. | $18.00 | 2024 | Nuzyra |
| Lexicon Pharmaceuticals, INC. | $17.49 | 2024 | |
| Viiv Healthcare Company | $16.81 | 2024 | Apretude |
| Phadia US INC. | $14.35 | 2024 | Immunocap |
| Phathom Pharmaceuticals, INC. | $10.33 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.